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Abstract
Background: To prevent importations of wild polioviruses into a polio free region a high level of
population immunity must be kept. Standard methodology for determination of polio antibodies is
a feature aimed at obtaining consistent results. An International Standard Serum for polio
antibodies exists, but no protective level in International Units is defined.
Methods: A representative study was carried out in order to determine the serological status
against poliomyelitis in Germany (n = 2564, age 18–79 years). Furthermore, sera from persons aged
less than 18 years were included (n = 881). Microneutralization test has been used for
determination of antibody levels. Results have been expressed in International Units.
Results: The results of this study indicate that the cut-off level for polio antibodies is 0.075 IU/ml
for Polio 1, 0.180 IU/ml for Polio 2 and 0.080 IU/ml for Polio 3. Neutralizing antibodies against
poliovirus type 1, 2 and 3 were detected in 96.2%, 96.8% and 89.6% of samples, respectively.
Conclusions: Overall, this seroprevalence indicates a very high level of immunity of the general
population. It must be kept after the switch of immunization strategy from attenuated to inactivated
vaccine in Germany.
Background
One of the strategic objectives of the WHO is the eradica-
tion of poliomyelitis in all regions of the world within the
next years. According to the WHO plans the transmission
of wild poliovirus has to be interrupted worldwide by the
end of 2002. The global certification will be held in 2005.
Although the European region is actually polio – free, it
remains subject to the risk of importation from endemic
regions. The most recent cases of poliomyelitis due to an
importation of wild polio type 1 occurred in unvaccinated
Bulgarian children [1]. To prevent such importations it is
necessary to keep a high level of population immunity.
The last indigenous case of poliomyelitis was diagnosed
in Germany in 1990. The last imported wild viruses were
detected in patients with travel history to India and Egypt
in 1992. Since that period of time there were found only
0 – 3 cases of vaccine-associated paralytic poliomyelitis
(VAPP) per year. In order to prevent these VAPP – cases
the vaccination strategy has been changed in Germany.
Since 1998 it is recommended to use only the inactivated
vaccine (IPV).
The neutralizing antibody test is the method of choice in
conducting serological surveys to identify epidemiologi-
cally important immunity gaps in the population. It is
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considered essential to provide the precise procedure for
carrying out polio neutralizing antibody tests. Use of
standard reagents, the International Standard Serum
(ISS), standard Sabin strains, and expression of the results
in International Units (IU) is a feature aimed at obtaining
consistent results. This will assure that comparison be-
tween studies can be made with confidence. An Interna-
tional Standard Serum does exist, but WHO
recommendations do not indicate a protective level in IU
[2,3].
Materials and methods
Serum samples
The first German Health Survey 1997/98 was a represent-
ative study of the health status of the population in uni-
fied Germany. In this project which has been carried out
by the Robert Koch Institute on behalf of the Ministry of
Health about 7200 study participants aged between 18
and 79 years were going through a medical check-up and
interviewed as to health – relevant issues. Germans as well
as foreigners, who lived in Germany, were included in the
survey. As a result of various selection criteria (age, sex,
and size of town) a representative collection of study par-
ticipants was obtained [4].
A representative panel of 2564 serum samples from the
total amount of sera from the Health Survey was investi-
gated for the presence of antibodies to all three poliovirus
serotypes.
Additionally, 881 sera from children less than 18 years ob-
tained from six large laboratories in Germany were in-
cluded in this study. These laboratories performed wide-
range diagnostics without any visible bias within the
group of patients. The sera were collected in 1996/97 and
stored at -20°C until testing.
Neutralization test
The microneutralization test using 100 ID50 of challenge
virus (Sabin strains) was performed according to the
WHO-guidelines [5][6]. An In-House Reference serum
(IHR) of known neutralizing activity was included in each
test to control reproducibility of results. Each test serum
was investigated in duplicate. If the final serum dilutions
of these duplicates differed more than one stage the test
was rejected.
The International Standard Serum (ISS, a preparation of
pooled human sera) containing 25 IU, 50 IU, and 5 IU for
Poliovirus 1, 2 and 3, respectively has been used to cali-
brate the potency of the IHR. ISS and IHR were titrated in
parallel on ten separate occasions using eight replicates
per serum dilution (starting from serum dilution of 1/4).
Calculation of the antibody concentration in International 
Units (IU/ml)
The calculation of the concentration with
resulted in CIHR1 = 3.125 IU/ml, CIHR2 = 6.25 IU/ml,
CIHR3 = 0,625 IU/ml for Polio 1, 2, 3, respectively for the
used IHR (example for Polio 1: a serum dilution ValISS =
1/256, and ValIHR = 1/32 would result in CIHR = 3.125 IU/
ml).
The calculation of the antibody concentration in a given
test serum sample was done analogously.
In contrast to WHO – recommendations not the geomet-
ric mean (GMT) of all measured IHR's was used but the
concentration of the IHR in the given test only. Thus each
test was calibrated in respect to the appropriate IHR.
A given test was only accepted if the final serum dilution
did not exceed a one-stage range of the GMT of all tested
and accepted IHR's. For an accepted test the following
condition holds:
The threshold values Co were calculated as follows:
with
SDev(C) = StandardDeviation{C, with serumdil. < 1/4}.
Results
In the past the cut-off value for "sufficiently protected"
against poliomyelitis was set if the final serum dilution
giving protection against 100 ID50 of challenge virus was
greater or equal to 1/4 (titer 8). This condition should be
substituted by expressing results in IU/ml.
C IU ml C IU ml
Val serumdil
Val serum
HR ISS
ISS
IHR
1 //
.
  =   ×
 
d dil.  
C IU ml C IU ml
Val serumdil
Val
sample IHR
IHR
sampl
//
.
  =   ×
 
e e serumdil.  
1
2
2 ×≤   ≤× − GMT Val serumdil GMT Test IHR . .
C CS D e v C 0 2 =+ × ()
C C =< {} Mean with serumdil ,. / 14BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/2
Page 3 of 4
(page number not for citation purposes)
The cut-off values (Co) for the protective level were calcu-
lated as follows:
for Polio 1: C0 = 0.080 IU/ml
for Polio 2: C0 = 0.180 IU/ml
for Polio 3: C0 = 0.075 IU/ml
Neutralizing antibodies against poliovirus type 1, 2 and 3
were detected in 96.2% (95% confidence interval CI:
95.5%-96.9%), 96.8% (CI: 96.1%-97.5%) and 89.6%
(CI: 88.4%-90.8%) of samples, respectively (Fig. 1). 85%
of all tested persons had antibodies against all three virus
types. Only 0.3% of tested persons had no detectable an-
tibodies against all polioviruses.
Statistically significant regional differences in the immu-
nity level between the adult populations in the East and
West of Germany have been detected for Polio 3 (86,6% /
90,9%; p = 0,001).
Within the given data set the decision "sufficiently pro-
tected" slightly changes according to Tab. 1 (expressing re-
sults in IU vs. serumdilution). Thus for Polio 3 about 3%
(82/2564) of the samples were additionally classified as
"not protected sufficiently " against disease.
Discussion / Conclusions
The goal of eradication of poliomyelitis has been compli-
cated by some events in 2000–2001. First, the discovery of
circulation of a vaccine virus strain that mutated to regain
its disease-causing ability in Hispaniola. This outbreak in
the Dominican Republic and Haiti was the first in the
Americas since 1991 and occurred in areas of very low vac-
cination coverage [7]. Second, the polio cases in Bulgaria.
There had been no reported cases of polio in Europa since
November 1998. In spring 2001 two gypsy unvaccinated
children were paralyzed by a wild poliovirus in Bulgaria,
which was imported from India [1]. These outbreaks send
a warning to all countries to maintain their guard against
polio, despite the rapid decline in its incidence. Sufficient
surveillance systems and high levels of population immu-
nity can prevent polio outbreaks.
The level of immunity to poliomyelitis has been checked
in Germany at regular intervals.
For the first time in Germany the results were expressed in
International Units. A representative serum panel from
the German Health Survey was investigated. Additionally,
sera from children less than 18 years old were included in
this study. These sera were not representative for all selec-
tion criteria because they originated from diagnostic labo-
ratories. A representative study of the health status of
persons under an age of 18 years is prepared by the Robert
Koch Institute. The pilot phase has started in 2001. Within
the next years valid data will be obtained for the younger
population of Germany.
The given threshold values of 0.075 lU/ml, 0.180 IU/ml,
and 0.080 IU/ml were calculated for Polio 1,2,3 respec-
tively. The calculation was based on the assumption that
the new criteria (threshold in IU/ml) should give compa-
rable results with respect to the old one (threshold of se-
rum dilution).
Overall, neutralizing antibodies against poliovirus type 1,
2 and 3 were detected in 96.2%, 96.8% and 89.6% of sam-
ples, respectively. This seroprevalence indicates a very
high level of immunity of the German population. Al-
Figure 1
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though the prevalence of antibodies against poliovirus
was generally somewhat lower for type 3 than for types 1
and 2, it was still close to 90%.
Data presented in this study are concordant to those ob-
tained in other countries [8,9].
A previous seroepidemiological study in Germany as well
as this one revealed substantial regional variations of im-
munity levels to Polio 3 [10]. Compared to the results of
this study other German studies have shown remarkable
lower antibody prevalence to Polio 3 among blood do-
nors in Berlin and in hospitalized patients [11,12].
Limitations in some of these serological studies due to
non-representative samples or methodological reasons re-
sulted in different conclusions regarding immunity status.
Standardization of the neutralization test as well as ex-
pressing results of serological studies in International
Units will permit better comparability of polio immune
status of populations in different studies, and in different
countries.
Immunity to poliomyelitis is largely dependent on hu-
moral neutralizing antibodies, both after natural infection
and after vaccination. It is unclear at present whether all
those persons with a low level or no detectable antibodies
are susceptible to infection; some, particularly the elderly,
may be protected by memory immunity, an accelerated
antibody response because the immune system has been
primed previously. It has also been shown that enterovi-
rus infections induce T-cell immunity [13]. The produc-
tion of local secretory IgA antibodies in the gut mucosa
may play a major role in protection [14,15].
Although IPV offers excellent protection against disease, it
is less effective in preventing poliovirus infection because
of limited mucosal immunity. IPV recipients may contrib-
ute to the circulation of outbreak virus. Extensive circula-
tion of Polio 3 was observed during 1984 outbreak in
Finland. A study from the Netherlands has also shown
that poliovirus circulation occurred during the early phase
of the 1992–93 poliomyelitis outbreak. Most infected
children had not been vaccinated [16]. A high level of im-
munity of the German population, including immigrants,
must be monitored after the switch from attenuated to in-
activated polio vaccine (OPV to IPV).
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Table 1: Differences in numbers of samples classified as "suffi-
ciently protected" (serumdilution vs. concentration C in IU/ml), 
n = 2564
Polio 1 C<C0 C>=C0
Serum dil.< 1/4 90 11
Serum dil.>=1/4 12 2451
Polio 2
Serum dil.< 1/4 97 17
Serum dil.>=1/4 1 2449
Polio 3
Serum dil.< 1/4 182 0
Serum dil.>=1/4 82 2300